Table 1.
Patients characteristics for each administration of new biologic users among rheumatoid arthritis patients during 2006–2013
| Patient Characteristics | Biologic Agents | |||||||
|---|---|---|---|---|---|---|---|---|
| Intravenous | Subcutaneous | |||||||
| ABA | GOL | INF | RIT | TOC | ABA | TOC | Injected anti-TNFs | |
| N of new users | 15,820 | 9 | 17,613 | 9,125 | 5,466 | 1,843 | 40 | 30,671 |
| N of administrations | 195,422 | 12 | 165,943 | 33,460 | 42,233 | 10,513 | 50 | 277,958 |
| Age, Mean (SD) | 68.8 (10.9) | 68.6 (7.3) | 69.0 (10.4) | 65.6 (12.1) | 66.3 (12.2) | 60.7 (12.5) | 56.0 (13.8) | 63.2 (12.8) |
| Age category, % | ||||||||
| <50 | 6.72 | 0.00 | 6.23 | 11.69 | 9.99 | 19.55 | 40.00 | 15.57 |
| 50–59 | 10.29 | 16.67 | 8.91 | 15.13 | 14.04 | 26.29 | 26.00 | 21.35 |
| 60–64 | 7.39 | 8.33 | 6.15 | 9.16 | 8.82 | 12.44 | 6.00 | 10.92 |
| 65–69 | 20.62 | 16.67 | 22.92 | 19.97 | 22.07 | 15.75 | 6.00 | 16.94 |
| 70–74 | 25.13 | 33.33 | 27.09 | 21.36 | 20.99 | 12.95 | 14.00 | 16.24 |
| 75–79 | 16.59 | 25.00 | 17.20 | 13.80 | 13.20 | 7.59 | 2.00 | 10.61 |
| 80–84 | 9.43 | 0.00 | 8.53 | 6.41 | 7.98 | 3.79 | 12.00 | 5.82 |
| >=85 | 3.82 | 0.00 | 2.96 | 2.48 | 2.92 | 1.65 | 4.00 | 2.55 |
| Female, % | 83.86 | 75.00 | 80.58 | 82.62 | 83.33 | 86.65 | 92.00 | 81.88 |
| Charlson Score, % | ||||||||
| 0 | 41.80 | 58.33 | 42.92 | 35.76 | 42.31 | 41.19 | 52.00 | 42.01 |
| 1 | 27.44 | 8.33 | 28.37 | 28.73 | 27.86 | 28.15 | 26.00 | 27.78 |
| 2 | 14.57 | 8.33 | 13.99 | 15.80 | 13.56 | 13.92 | 14.00 | 13.72 |
| 3+ | 16.19 | 25.00 | 14.72 | 19.71 | 16.27 | 16.75 | 8.00 | 16.49 |
| Methotrexate, mg/week, % | ||||||||
| None | 53.38 | 50.00 | 36.31 | 56.61 | 56.93 | 57.64 | 48.00 | 49.48 |
| >0–<=10 | 22.17 | 41.67 | 27.29 | 22.10 | 20.04 | 19.72 | 22.00 | 22.33 |
| >10–<=15 | 12.43 | 0.00 | 17.10 | 10.17 | 10.67 | 9.34 | 12.00 | 13.17 |
| >15–<=20 | 9.41 | 8.33 | 15.15 | 8.43 | 8.98 | 8.90 | 10.00 | 11.37 |
| >20 | 2.61 | 0.00 | 4.14 | 2.69 | 3.39 | 4.41 | 8.00 | 3.64 |
| Prednisone, % | ||||||||
| None | 48.87 | 33.33 | 51.57 | 40.30 | 43.60 | 39.79 | 58.00 | 50.23 |
| 0< 7.5 | 37.78 | 50.00 | 36.20 | 39.22 | 36.43 | 33.21 | 36.00 | 35.59 |
| >7.5 | 13.35 | 16.67 | 12.23 | 20.48 | 19.97 | 27.00 | 6.00 | 14.18 |
| Same day steroid infusion for all administrations, % | ||||||||
| 5.5 | 0.0 | 11.7 | 79.4 | 8.8 | 0.6 | 0.0 | 0.9 | |
| N of prior biologic use, % | ||||||||
| 0 | 29.94 | 25.00 | 67.56 | 19.73 | 8.68 | 11.35 | 2.00 | 50.52 |
| 1 | 51.35 | 25.00 | 23.36 | 41.72 | 33.08 | 36.21 | 34.00 | 34.77 |
| 2 | 14.81 | 16.67 | 6.43 | 26.84 | 35.25 | 34.43 | 34.00 | 10.07 |
| 3 or greater | 3.89 | 33.33 | 2.65 | 11.71 | 22.99 | 18.01 | 30.00 | 4.63 |
ABA = Abatacept, INF = infliximab, RIT = Rituximab, TOC = Tocilizumab, GOL = Golimumab